Real solutions to rare challenges. That’s our target.

Idera Pharmaceuticals is a biopharmaceutical company with a commitment to bring breakthrough therapies to patients who need them most by acquiring, developing, and ultimately commercializing treatments for rare diseases indications characterized by small, well-defined patient populations with serious unmet needs.

Furthering our commitment to this goal, in September 2022 Idera merged with Aceragen, Inc., a privately-held biotechnology company addressing rare, orphan pulmonology and rheumatology diseases that typically have no treatment. To learn more about Aceragen, visit Aceragen.